Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for 60 Degrees Pharmaceuticals's EV-to-OCF or its related term are showing as below:
SXTP'
s EV-to-OCF Range Over the Past 10 Years
Min: -42.36 Med: -1.68 Max: -1.03
Current: -1.16
During the past 6 years, the highest EV-to-OCF of 60 Degrees Pharmaceuticals was -1.03. The lowest was -42.36. And the median was -1.68.
SXTP's EV-to-OCF is ranked worse than 63.11% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs SXTP: -1.16
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
60 Degrees Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
60 Degrees Pharmaceuticals's share price for today is $1.11.
60 Degrees Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.038.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
60 Degrees Pharmaceuticals EV-to-OCF Related Terms
60 Degrees Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's EV-to-OCF falls into.
60 Degrees Pharmaceuticals's current Enterprise Value is $9.25 Mil.
60 Degrees Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
60 Degrees Pharmaceuticals (SXTP) has a EV-to-OCF of -1.16 as of Aug. 09, 2026. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #888 out of 1407 companies in the Biotechnology industry, placing it in the top 63.1%.
Is 60 Degrees Pharmaceuticals' EV-to-OCF too high?
60 Degrees Pharmaceuticals' current EV-to-OCF is -1.16. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #888 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' EV-to-OCF compare to GNPX and GLMD?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #888 out of 1407 companies for EV-to-OCF. This places 60 Degrees Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. 60 Degrees Pharmaceuticals's current EV-to-OCF is -1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Possible Value Trap. The stock's GF Value™ is $1.66, compared to a current price of $1.11 — trading 33.1% below its estimated fair value. The current EV-to-OCF is -1.16. 60 Degrees Pharmaceuticals' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current EV-to-OCF is -1.16 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.11 is trading 33.1% below its estimated GF Value™ of $1.66.
GuruFocus considers 60 Degrees Pharmaceuticals to be Possible Value Trap.
Key valuation signals for SXTP:
EV-to-OCF: -1.16
GF Value™: $1.66 vs. price of $1.11 (33.1% below fair value)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
58GF Score
Get the complete analysis for SXTP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 
